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Summary
The Clinical Practice Research Datalink (CPRD) is an ongoing primary care database of ano-
nymised medical records from general practitioners, with coverage of over 11.3 million
patients from 674 practices in the UK. With 4.4 million active (alive, currently registered)
patients meeting quality criteria, approximately 6.9% of the UK population are included
and patients are broadly representative of the UK general population in terms of age, sex
and ethnicity. General practitioners are the gatekeepers of primary care and specialist re-
ferrals in the UK. The CPRD primary care database is therefore a rich source of health
data for research, including data on demographics, symptoms, tests, diagnoses, thera-
pies, health-related behaviours and referrals to secondary care. For over half of patients,
linkage with datasets from secondary care, disease-specific cohorts and mortality re-
cords enhance the range of data available for research. The CPRD is very widely used
internationally for epidemiological research and has been used to produce over 1000 re-
search studies, published in peer-reviewed journals across a broad range of health out-
comes. However, researchers must be aware of the complexity of routinely collected
electronic health records, including ways to manage variable completeness, misclassifi-
cation and development of disease definitions for research.
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Data Resource Profile
Data resource basics
UK primary care data for research
Over 98% of the UK population are registered with a pri-
mary care general practitioner (GP)1 and under the
National Health Service (NHS), visits to the GP are free of
charge. The GP is the gatekeeper of care in the UK
National Health Service. GPs act as the first point of con-
tact for any non-emergency health-related issues, which
may then be managed within primary care and/or referred
to secondary care as necessary. Secondary care teams also
feed back information to GPs about their patients, includ-
ing key diagnoses. Patient data are routinely recorded onto
computers by practice staff, against a unique patient NHS
number. These facets of UK primary care provide good
capture of health information in a longitudinal electronic
health record.
The Clinical Practice Research Datalink (CPRD)
The CPRD harnesses general practice data and produces a
primary care dataset, which is one of the largest databases
of longitudinal medical records from primary care in the
world (Table 1). Established in London in 1987, the small
Value Added Medical Products (VAMP) dataset grew to
become the General Practice Research Database (GPRD)
in 1993,2,3 before expanding to become the CPRD in
2012. The CPRD collates routinely collected anonymised
electronic health record data from general practices who
have agreed at a practice level to provide data on a
monthly basis. All patients registered with the participating
practices are included in the dataset, unless they have indi-
vidually requested to opt out of data sharing, by asking
their GP to amend their registration details on the system
to disable the extraction of their data.
Data linkage
A subset of English practices (currently 75%, representing
58% of all UK CPRD practices) have consented to partici-
pate in the CPRD linkage scheme and have provided
patient-level information. Patient-level data from consent-
ing practices are linked via a trusted third party
(the Health and Social Care Information Centre4) to other
existing data sources. Established linkages include
Hospital Episode Statistics5 (hospitalisation data), Office
for National Statistics6 (mortality data including causes of
death), Index of Multiple Deprivation and Townsend
scores (deprivation data)and disease registries including
the National Cancer Intelligence Network,7 and the
Myocardial Ischaemia National Audit Project8 (details in
Supplementary Table 1, available as Supplementary data
at IJE online). Other linkages are planned (see CPRD web-
site9) and researchers can make requests for bespoke link-
age for individual studies.
Uses for observational research and
interventional research
Subject to the appropriate data governance and approvals,
the CPRD can supply primary care and linked patient data
to researchers in the UK and internationally. Through the
CPRD, researchers can approach practices and patients to
take part in biosample collection studies or trials. The
feasibility of this work has been tested: patients from the
CPRD have been recruited to a pharmacogenetic study of
statin-induced myopathy,10,11 practices have been
recruited to cluster randomised trials12,13 and patients
have been recruited to pragmatic point-of-care randomised
trials.14 The electronic health record data can be used
alongside the study data to provide a full clinical picture
for the recruited patients.
Key Messages
• CPRD data have been extensively used for observational research. For example, the data were used to show that
there was no association between MMR vaccine and autism, and to show an association between oral corticosteroid
use and increased risk of fractures.
• The CPRD has a large UK dataset bringing together longitudinal primary care medical records from participating prac-
tices. Over half of CPRD patients are eligible for linkage to additional datasets, including hospital data, national cancer
registration data and national mortality records.
• Quality of some data is driven by the Quality and Outcomes Framework in the UK, and data are also monitored by
CPRD internal processes. Analyses described in this paper show that active (alive, currently registered) CPRD patients
are representative of the UK population in terms of age and sex.
• CPRD data originate from routine clinical practice, and their use for epidemiological studies typically requires exten-
sive data processing and an understanding of the way the data are originally recorded and stored.
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Ethics
The CPRD has broad National Research Ethics Service
Committee (NRES) ethics approval for purely observa-
tional research using the primary care data and established
data linkages. Other uses of CPRD data may require separ-
ate ethical approval. This is likely if there is any specific
patient involvement in the study; for example, if the
researcher wishes to ask patients to complete a question-
naire for Patient Reported Outcomes, or to conduct an
interventional trial among CPRD patients.
Data governance, practice and patient
confidentiality
The CPRD strives to operate within UK and European
laws to protect confidentiality. Governance requirements
to protect patient confidentiality where patient consent has
not been obtained are respected by ensuring that patient
identifiers are held separately from the clinical data and
that there is separation between researchers with access to
identifiable information from the primary study and those
using CPRD data.
Funding sources
The CPRD is a joint venture from the Medicines and
Healthcare Regulatory Agency (MHRA) and the National
Institute for Health Research (NIHR).The CPRD is owned
by the UK Department of Health and operates within the
MHRA. The CPRD has received funding for studies from the
MHRA, Wellcome Trust, Medical Research Council, NIHR
Health Technology Assessment programme, Innovative
Medicines Initiative, UK Department of Health, Technology
Strategy Board, Seventh Framework Programme EU and
various universities, contract research organizations and
pharmaceutical companies.
Data resource area and population coverage
Figure 1 describes the population coverage of CPRD pri-
mary care data across England, Wales, Scotland and
Northern Ireland. At the mid-year date of 2 July 2013, the
dataset held information on 11.3 million patients who
were deemed acceptable for research based on data quality
checks (Appendix 1, available as Supplementary data at
IJE online, and described below). The population of active
patients (alive and currently registered) on 2 July 2013 was
4.4 million, representing 6.9% of the total UK population
(based on the UK 2013 mid-year population of 64.1
million). The remaining 6.9 million records represent
inactive patients who have died or are no longer registered
with a participating practice. Patient numbers by age, sex,
deprivation, ethnicity and region are described in Table 2.
Frequency of data collection
Data collection happens as part of normal clinical care of
patients in participating practices on a daily basis. The fre-
quency of data recording is determined by patient need
and varies by age, sex and underlying morbidity. Patients
are included in the primary care dataset from their first
until their last contact with the participating practice. Data
are collected by practices and usually uploaded to the
CPRD secure servers on a monthly basis. The date of last
data collection corresponds to the date of the last data up-
load from each practice. Monthly builds of the primary
care dataset are generated and made available for
researchers to use.
Measures
Practice and patient data
The database structure broadly separates information into
clinical, referral, immunisation, test and therapy data
Table 1. Key details about the Clinical Practice Research Datalink
Counties participating UK: England, Wales, Scotland and Nortdern Ireland
Who is included? Patients registered at general practices that contribute data to CPRD, who have not dissented from sec-
ondary use of GP patient-identifiable data
What is recorded? Demographics, diagnoses, symptoms, signs, prescriptions, referrals, immunisations, behavioural factors,
tests
Period of data collection 1987 to present
Average duration of follow-up 5.1 years
Funding source CPRD has received funding from the MHRA, Wellcome Trust, Medical Research Council, NIHR Health
Technology Assessment programme, Innovative Medicines Initiative, UK Department of Health,
Technology Strategy Board, Seventh Framework Programme EU, and various universities, contract re-
search organizations and pharmaceutical companies
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(see Supplementary Table 1, available as Supplementary
data at IJE online). Data are recorded against practice and
patient pseudo-identifiers. At the practice level, geographical
region is recorded by the CPRD as one of 10 regions in
England, with Wales, Scotland and Northern Ireland as sep-
arate regions (Figure 1); a practice-level deprivation score is
also calculated based on practice lower super output area.
All general practice encounters are recorded electronic-
ally and practitioners are encouraged to make these re-
cords available for research. Data are collected on
demographic information, prescription details, clinical
events (symptoms, diagnoses), preventive care provided,
tests, immunisations, specialist referrals, hospital
admissions and their major outcomes, and details relating
to death (details are shown in Supplementary Table 2,
available as Supplementary data at IJE online).
All entries to a patient record are considered as ‘consult-
ations’, not all of which will involve a face-to-face encoun-
ter. Within a consultation multiple ‘events’ may be
recorded, each with an associated date (Figure 2).
Data are largely recorded by general practice staff using
version 2 Read codes, a hierarchical clinical classification sys-
tem containing over 96, 000 codes.15 For example, during a
consultation, a GP, nurse, other healthcare professional, prac-
tice manager or administrator may enter a number of Read
codes to describe a patient’s condition (e.g. lifestyle measures
Figure 1. Distribution of 674 CPRD practices by region in England, and in Wales, Scotland and Northern Ireland.
Note: practices mapped are those contributing up to standard data to the dataset on 2 July 2013, based on the January 2014 dataset build
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such as smoking status, symptoms, past medical history, diag-
noses, tests performed such as blood pressure measurement,
and therapies offered). Numerical data on additional clinical
measures (e.g. height, weight, blood pressure, alcohol intake)
can also be recorded during consultations. Prescriptions
issued by the GP are automatically recorded with a product
name and British National Formulary code, alongside the
dosage instructions and quantity. Results of laboratory tests
ordered by the GP are commonly added to the patient record
via electronic links to laboratories. Data fed back to the GP
from other sources may also be entered into the patient
record by practice staff; this might include information from
secondary care such as key diagnoses, discharge data from
hospitals, or follow-up information from specialist clinics.
Table 2. Demographic characteristics of acceptable CPRD patients (January 2014 dataset
build), and the subset of those active on 2 July 2013
All patients Active
No. patients 11299221 4425016
Men, n (%) 5478715 (48.5) 2183161 (49.3)
Women, n (%) 5820506 (51.5) 2241855 (50.7)
Age in 2013, n (%) (years)
<18 – 742765 (20.2)
18-64 – 4402926 (61.8)
65þ – 1728514 (18.1)
Region, n (%)
North East 184753 (1.6) 67639 (1.5)
North West 1257846 (11.1) 523356 (11.8)
Yorkshire & The Humber 441933 (3.9) 48480 (1.1)
East Midlands 446799 (4) 29954 (0.7)
West Midlands 943011 (8.4) 394115 (8.9)
East of England 1117235 (9.9) 306538 (6.9)
South West 943295 (8.4) 377821 (8.5)
South Central 1236351 (10.9) 544979 (12.3)
London 1532066 (13.6) 600824 (13.6)
South East Coast 1130468 (10) 474593 (10.7)
Northern Ireland 275640 (2.4) 153576 (3.5)
Scotland 960121 (8.5) 499969 (11.3)
Wales 829703 (7.3) 403172 (9.1)
Duration of follow-up
(median years, IQR)a
5.1 (1.8-11.1) 9.4 (3.4-13.9)
Active patients are alive and currently registered on 2 July 2013.
aIncludes only up to standard follow-up.
Figure 2. Example of dataset structure.
Note: patients consult with practice staff, where clinical, therapy, referral, test and immunisation information is coded in the medical record.
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The GP is also able to make additional uncoded notes
and observations about patients as free text. This often
contains identifiable information and is not part of the
standard database available to researchers.
Data resource use
Data from the CPRD (or formerly the GPRD or VAMP)
have been used in the UK and internationally16 to produce
close to 2000 research reports, with over 1000 published
in peer-reviewed journals, across all major therapeutic
areas. A bibliography is maintained by the CPRD and is
available online.17 These publications cover a range of
health-related research topics including pharmacoepidemi-
ology, comparative effectiveness research, health services
research, assessments of temporal trends in disease inci-
dence, health economics, prognosis research, classical risk
factor epidemiology and more recently randomised con-
trolled trials.12,18 Publications to date include studies
showing the absence of an association between measles,
mumps and rubella (MMR) vaccine and autism,19 cardio-
vascular risk after acute infection,20 the lower risk of
dementia associated with statin use,21 the risk of myocar-
dial infarction in patients with psoriasis,22 the use of oral
corticosteroids and fracture risk23 and the association
between body mass index and cancer.24
Strengths and weaknesses
Strengths
The strengths of the CPRD data as a research resource lie
in the breadth of coverage, size, long-term follow-up, rep-
resentativeness and data quality.
Breadth of data
The CPRD primary care dataset is one of few large,
ongoing databases that include data on morbidity and life-
style variables and with a linkage to secondary care and
mortality data.
Size and long- term follow-up
A key strength of this database is its size; the CPRD holds
data from 674 practices and includes over 79 million per-
son-years of follow-up (on 2 July 2013, January 2014 data-
set). This allows epidemiological associations to be
investigated in more detail and estimated with a higher
level of statistical precision than is possible with smaller
data sources, which is of particular importance for the
study of rare exposures and diseases.25,26 For individual
patients, there is a median prospective follow-up of
9.4 years for active patients [interquartile range (IQR)
3.4–13.9] and 5.1 years (IQR 1.8–11.1 years) (Table 2)
overall, enabling research into diseases with long latency
and the study of long-term outcomes.27–29
Representativeness
When compared with the UK census in 2011,30 CPRD
patients are broadly representative of the UK population in
terms of age and sex (Figure 3). Patients are also compar-
able to the UK census in terms of ethnicity,31 and compar-
able to the Health Survey for England for body mass index
distribution in most patient subgroups.32 However, the
CPRD may not be representative of all practices in the UK
based on geography and size.33
Data quality
Aspects of data quality in English general practice are
enhanced by the Quality and Outcomes Framework,34 an
incentive payment programme for GPs, which encourages
recording of key data items (for example smoking status
and the delivery of services to key patient groups). The
Quality and Outcomes Framework was introduced in 2004,
and completeness in recording of many variables showed
subsequent improvement (Figure 4, and Supplementary
Figure 1, available as Supplementary data at IJE online).
Validation of the CPRD has shown high positive pre-
dictive value of some diagnoses and, where evaluated,
comparisons of incidence with other UK data sources are
also broadly similar.35–38 However, reporting of validation
studies was often too poor to permit a clear interpretation,
and the majority of studies focused on positive predictive
value rather than sensitivity or specificity.39
The quality of primary care data is variable because data
are entered by GPs during routine consultations, not for the
purpose of research. Researchers must therefore undertake
comprehensive data quality checks before undertaking a study.
The CPRD provides two sets of data quality criteria: accept-
ability for patients and up to standard (UTS) time for practices.
These criteria do not ensure data quality, but the CPRD recom-
mends that these measures are used as a first step to selecting
research-quality patients and periods of quality data recording.
The acceptable patient metric is based on registration status, re-
cording of events in the patient record, and valid age and gen-
der. The UTS date is a practice-based quality metric based on
the continuity of recording and the number of recorded deaths.
The UTS date is calculated for each participating practice, cor-
responding to the latest date at which practices meet these min-
imum quality criteria (Appendix 1, available as Supplementary
data at IJE online). The figures given in this paper reflect data
for patients labelled as acceptable and who have at least 1 day
of follow-up that is ‘up to standard’. Research into data quality
has shown that, despite these criteria, there were large vari-
ations in inter-practice recording of data.40
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Weaknesses
Missing data
The variability in completeness of data across patients and
across time requires careful consideration; restriction to
those with complete data may result in biased analyses, and
imputation may not be a straightforward approach because
the patterns of missingness are complex. For example, body
mass index may be recorded more frequently in patients
with a health issue, and blood pressure more frequently in
women of reproductive age and those with existing cardio-
vascular disease. Complex algorithms are often required to
deal with missingness, to resolve discrepancies in measures
between consultations and to decide whether historical
measurements, for example of body mass index, blood
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Figure 3. Age distribution of the CPRD primary care data on 27 March 2011 compared with UK Census data 2011, in men (top panel) and women
(lower panel). These data are based on a one-million patient sample of CPRD. All patients are acceptable.
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pressure or smoking status, are still appropriate to a
patient’s disease risk much later in follow-up.32
An additional complexity of primary care data is that the
absence of a Read code for disease must be interpreted as an
absence of the disease itself, so whereas positive predictive
value tends to be high,39 sensitivity may be lower. This
potential misclassification arises partly due to patients fail-
ing to present to the GP with disease, and also from varia-
tions between GPs in coding diagnoses in the patient
electronic record; if GPs enter information as free text,
researchers will miss valuable information. The extent of
misclassification may vary between diseases.39
Definitions
There are not generally standardised definitions for diag-
noses and other details, so Read code lists and algorithms
need to be developed for each study to identify exposures
and outcomes of interest. This may lead to inconsistent
definitions (and therefore results) between studies using
the same data.
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Note: Based on a random sample of one million acceptable patients. Adults aged 18+ were included. Records outside of UTS were included.
Denominators are mid-year registered populations. Total cholesterol has poorer completeness as this would not be routinely recorded and
would require a clinical indication. Completeness of ethnicity recording for new registrants after 2004 approached 70% in 2011.(31)
Note: based on a random sample of one million acceptable patients. Adults aged 18+ were included. Records outside of UTS were included.
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Figure 4. Recording of key lifestyle and demographic variables by calendar year (A: ever recorded in patient follow-up; B: recorded in the past 3 years
of patient follow-up). These data are based on a one-million patient sample of primary care data from the CPRD. All patients are acceptable.
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Information from secondary care
General practices receive information about patient con-
tacts with secondary care but this information must be
manually entered into the patient record. Therefore, details
about hospital admissions (dates, diagnoses, tests per-
formed, length of stay) may be incomplete.
Data not captured
Some aspects of health may be recorded very infrequently or
not at all, for example level of social support, number of peo-
ple in a household, over-the-counter medication use, prescrip-
tions in secondary care, prescriptions filled, and adherence to
treatments. There are also certain patient groups that are
missing from primary care records, such as prisoners, private
patients, some residential homes and the homeless.
Data Resource access
Access to patient level data is provided by the CPRD for
health research purposes and is dependent on approval of a
study protocol by the MHRA Independent Scientific
Advisory Committee (ISAC).
Researchers intending to use the data should be aware
that the CPRD data files contain millions of rows of data,
requiring extensive data management and an in-depth
understanding of the way the data are input and stored.
The CPRD provide data dictionaries and coding dic-
tionaries to researchers, and guidance on creating code lists
is available to help identify codes of interest.41 Read code
repositories for electronic health record research are also
now available.42,43
Details about ISAC applications and data costs are avail-
able on the CPRD website, and any other queries can be
directed to the CPRD Knowledge Centre [kc@cprd.com].9
Supplementary Data
Supplementary data are available at IJE online.
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